Fewer than one in 10 individuals that would benefit from obesity jabs like Wegovy have access to them, caution the WHO as it issues its initial recommendations on the therapies.
Considering in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for increased and just access to GLP-1 medication.
Per projections, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"The latest guidelines recognises that excess weight is a chronic disease that can be managed with thorough and continuous support," stated WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant obstacles to universal availability to the treatments that can aid individuals in losing significant body mass, explains the organization.
GLP-1 Therapy Scarcity
Even in the current best projected scenario, the production of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of eligible patients, according to the WHO.
The guideline encourages governments and firms to increase availability, through measures like voluntary licensing.
Exclusive production rights on semaglutide – the primary ingredient of a leading brand – is scheduled to end in multiple nations in 2026.
The Way Weight-Loss Injections Function
GLP-1 drugs mimick a biological compound to reduce digestion speed, suppress the appetite and increase the sense of being full so people reduce food intake.
Patients commonly begin shedding pounds in the initial weeks of starting on the once-weekly jabs.
Evidence suggests users may see weight return within a year of stopping the treatment, because their normal food cravings resume.
To be overweight or obese increases your chance for experiencing medical conditions, such as diabetes, cardiovascular issues, brain attack, and certain cancers.
Obesity impacts individuals in countries worldwide and was linked to over three and a half million deaths worldwide in 2024, as per the health agency.
